Compare PKE & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PKE | CADL |
|---|---|---|
| Founded | 1954 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 679.4M | 578.8M |
| IPO Year | 1994 | 2021 |
| Metric | PKE | CADL |
|---|---|---|
| Price | $32.60 | $9.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 410.2K | ★ 1.9M |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.53% | N/A |
| EPS Growth | ★ 93.10 | 58.62 |
| EPS | ★ 0.56 | N/A |
| Revenue | N/A | ★ $125,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $59.45 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.78 | $4.35 |
| 52 Week High | $38.20 | $9.57 |
| Indicator | PKE | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 47.63 | 62.96 |
| Support Level | $31.27 | $4.80 |
| Resistance Level | $35.94 | $9.42 |
| Average True Range (ATR) | 1.82 | 0.63 |
| MACD | -0.17 | -0.00 |
| Stochastic Oscillator | 32.53 | 76.53 |
Park Aerospace Corp is an aerospace company that develops and manufactures composite materials used to produce composite structures for the aerospace market. Its products include film adhesives, lightning strike protection materials, specialty ablative materials for rocket motors and nozzles, and materials for radome applications. The Company offers composite materials designed for hand lay-up and automated fiber placement (AFP) manufacturing applications, which are used in jet engines, large and regional transport aircraft, military aircraft, unmanned aerial vehicles (UAVs), business jets, general aviation aircraft, and rotary wing aircraft. It operates in North America, Asia, and Europe, with North America generating maximum revenue.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.